24 reports

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Endocrine Disease
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

AstraZeneca is one of the leaders involved in developing such a drug.

  • Endocrine Disease
  • Therapy
  • United States
  • Forecast
  • Market Size

SEMAGLUTIDE, A ONCE-WEEKLY HUMAN GLP-## ANALOG, DOES NOT REDUCE THE BIOAVAILABILITY OF THE COMBINED ORAL CONTRACEPTIVE, ETHINYLESTRADIOL/ LEVONORGESTREL.

  • Endocrine Disease
  • Market Size
  • AstraZeneca PLC
  • Novo Nordisk Group
  • Sanofi S.A.

MERCK' S CONTRACEPTIVE RING, NUVARING SHOWED SERIOUS SIDE EFFECTS ON THE CONSUMERS.

  • Endocrine Disease
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited

Semaglutide, a Once-Weekly Human GLP-## Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/ Levonorgestrel.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Metformin and Oral Contraceptives Vs.

  • Clinical Trial
  • Endocrine Disease
  • Hormone
  • Therapy
  • World

Metformin and Oral Contraceptives Vs.

  • Clinical Trial
  • Endocrine Disease
  • Hormone
  • Pharmaceutical
  • World

Liver enzymes ## × upper limit of normal occurred in four patients (fasiglifam ## mg, n = ##; fasiglifam ## mg, n = ##; ## fasiglifam/ sitagliptin ##/ ## mg, n = ##).

  • Diabetes
  • Endocrine Disease
  • Therapy
  • Type 2 Diabetes
  • Takeda Pharmaceutical Company Limited

One Way Liver ##.

  • Endocrine Disease
  • United States
  • Enterome Bioscience SA
  • MicroBiome Therapeutics LLC
  • Seres Therapeutics, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Monoclonal Antibody
  • Pharmaceutical
  • World

GLP-## binds to GLP-## receptors on the beta cells of the pancreas and increases the release of insulin.

  • Endocrine Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • XERIS Pharmaceuticals, Inc.
  • Clinical Trial profile. 321 Trial Title

The prominent features of this report are - ##.

  • Drug Development
  • Endocrine Disease
  • Pharmaceutical
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Endocrine Disease
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.

Hoffmann-La Roche Ltd Merck & Co Inc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## GlaxoSmithKline Plc DSM Biologics Holdings Inc ## ## ## ## ## ##

  • Clinical Trial
  • Endocrine Disease
  • World
  • Product Initiative
  • Amgen Inc.

## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## GlaxoSmithKline Plc Bristol-Myers Squibb Co ProSciento Inc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Novartis AG

  • Clinical Trial
  • Endocrine Disease
  • Insulin
  • Therapy
  • World

The prominent features of this report are - ##.

  • Chronic Disease
  • Clinical Trial
  • Endocrine Disease
  • World
  • Novartis AG

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Endocrine Disease
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

It also offers contraceptive agents, chemotherapeutics, and other products.

  • Cardiovascular Disease
  • Chronic Disease
  • Endocrine Disease
  • Therapy
  • Esperion Therapeutics, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Endocrine Disease
  • Pharmaceutical
  • World
  • Clinical Trial Profile Snapshots

GlaxoSmithKline Plc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2016 2016 trials are taken as of June 2016 exendin-(##-##) alone or in combination h

  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative

Ltd. ## Feb 2013 ## Mar 2013 ## ## ## ## HMG-CoA Reductase Inhibitor ##-Hydroxy-##-Methylglutaryl-Coenzyme A Reductase (HMG-CoA Reductase or Hydroxymethylglutaryl-CoA Reductase or EC ##. ##. ##. ##) Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Development
  • Endocrine Disease
  • World

It also offers ETC products in the areas of cardio vascular, CNS, digestive system, contraceptives, endocrine and oral diseases.

  • Endocrine Disease
  • United States
  • World
  • Company
  • Product Initiative

It also offers ETC products in the areas of cardio vascular, CNS, digestive system, contraceptives, endocrine and oral diseases.

  • Cardiovascular Disease
  • Endocrine Disease
  • United States
  • Company
  • Product Initiative